🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's negotiated accords with the US administration are "fundamentally unstable." This comes after revelations that a much-touted deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "significant" achievement, is still an "agreement in principle" without detailed provisions. Critics have noted that the public statements from the UK and US governments frame the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a singular success, while the American announcement highlights the commitment for the NHS to pay higher prices for new medications.

"The danger exists that the UK government has made commitments to increase medicine costs in return for little more than a pledge from President Trump," said David Henig, a trade policy analyst. "We know he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Concerns have been amplified by Washington's action to suspend the major technology agreement, which was previously described as "a transformative pact" in the bilateral relationship. The US pointed to a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a looming January deadline. "Our understanding is that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have admitted unease that the government's agreements with the US are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than the administration's tactics is the UK government's credulous faith that his administration is a good faith actor. The NHS is of vital importance."

Official Reassurances and Concrete Outcomes

Government figures have downplayed the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that unpredictability is inherent in dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Yet, issues have arisen in implementing the initial US-UK accord. Promised reciprocal agricultural allowances have failed to be approved, and the assurance to "reduce steel tariffs to zero" has remains unmet, with tariffs fixed at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.